| HALOZYME THERAPEUTICS |
| USA |
| Gesundheit |
| US40637H1095 / A0DLHS |
| RV7 (Frankfurt) |
| FRA:RV7, ETR:RV7, RV7:GR |
| - |
| https://halozyme.com/ |
|
Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions. The company focuses on enhancing the administration of biologic and other injectable therapies through its proprietary E..
>Volltext.. |
| 8462.55 Mio. EUR |
| 10039.93 Mio. EUR |
| 1308.16 Mio. EUR |
| 833.06 Mio. EUR |
| 302.52 Mio. EUR |
| 2.53 EUR |
| 1859.87 Mio. EUR |
| 268.62 Mio. EUR |
| 587.47 Mio. EUR |
| 0.88 |
| 30.26% |
| -32.7% |
| - |
| - |
| - |
| - |
| HALOZYME |
| 07.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|